Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
Themis will market this drug with the brand name REMITHEM.
Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer
Thermo Fisher and Celltrio bring first-in-kind automation platform to address critical scale-up challenges in biotherapeutics RoboCell cell line automation platform
The Ministry of Ayush endeavour is to get entry level NABH certification for 12,500 Ayush Wellness Centers by the end of 2023
She is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and Stryker India Pvt. Ltd.
Subscribe To Our Newsletter & Stay Updated